EUVIMEDEUVIMED entdecken
Crossref

Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429‐dependent m6A modification of CCR9

Zhao Lv, Lijuan Liu, Jian You, Ping Zhou, Yaru Su, Kexin Zhao, Jiahang Zhang, Fan Zhu

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Zhao Lv und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology, Department of Medical Microbiology, School of Basic Medical Sciences, Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Hepatitis B virus, RNA-Binding Proteins, Hepatitis B Surface Antigens, Antiviral Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: The National Natural Science Foundation of China, The Fundamental Research Funds for the Central Universities, The Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A substantial body of literature, including our own, points to a connection between hepatitis B virus (HBV) infection and the development of drug resistance in hepatocellular carcinoma (HCC), particularly against sorafenib. However, the influence of HBV on resistance to regorafenib, another therapeutic agent, has been less studied. In this study, we used the GEO database (GSE87630) and clinical samples to demonstrate that C‐C motif chemokine receptor 9 (CCR9) was highly expressed in HBV‐related HCC and predicted poor overall survival. Its overexpression correlated with HBsAg‐positive HCC patients. Both univariate and multivariable Cox regression analysis elucidated CCR9 was an independent risk factor for poor overall survival in HCC patients. Our in vitro findings further revealed that HBV structural proteins, small HBV surface antigen (SHBs), triggered an upregulation of CCR9. Functional assays showed that SHBs enhanced HCC cell proliferation, migration, and invasion, increased ABCB1 and ABCC1 expression, and promoted regorafenib resistance via CCR9. Intriguingly, overexpression of HBV plasmid and an AAV‐HBV mouse model both exhibited a significant elevation in global N6‐methyladenosine (m6A) levels. Further investigations revealed that SHBs elevated these m6A levels, upregulated CCR9 and stabilized CCR9 mRNA through KIAA1429‐mediated m6A modification, with sites 1373 and 1496 on CCR9 mRNA being critical for modification. In conclusion, SHBs promoted HCC progression and regorafenib resistance via KIAA1429‐mediated m6A modification of CCR9. Our findings suggested that CCR9 could be a potential prognostic biomarker and a valuable molecular therapeutic target of regorafenib resistance in HBV‐related HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusRNA-Binding ProteinsHepatitis B Surface AntigensAntiviral AgentsCarcinoma, HepatocellularLiver NeoplasmsReceptors, CCRAdenosineDrug Resistance, ViralAnimalsMiceMice, Inbred C57BLHumansPhenylurea CompoundsPyridinesPrognosisMaleFemaleMiddle AgedRNA, Messenger

Stichwörter der Autor:innen

C‐C motif chemokine receptor 9 (CCR9)KIAA1429hepatocellular carcinoma (HCC)regorafenib resistancesmall hepatitis B virus surface antigen

Substanzen

N-methyladenosineAdenosineVIRMA protein, humanRNA-Binding ProteinsHepatitis B Surface AntigensregorafenibPhenylurea CompoundsPyridinesAntiviral AgentsCC chemokine receptor 9

Autor:innen und Institutionen

  • State Key Laboratory of Virology, Department of Medical Microbiology, School of Basic Medical Sciences, Wuhan University, Wuhan, China.
  • Hubei Province Key Laboratory of Allergy and Immunology, Wuhan University, Wuhan, China.
  • Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory…

Förderung

  • The National Natural Science Foundation of China
  • The Fundamental Research Funds for the Central Universities
  • The Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University

Zitieren

APA

Lv, Z., Liu, L., You, J., Zhou, P., Su, Y., Zhao, K., Zhang, J., & Zhu, F. (2024). Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429‐dependent m6A modification of CCR9. Journal of Medical Virology. https://doi.org/10.1002/jmv.29894

Vancouver

Lv Z, Liu L, You J, Zhou P, Su Y, Zhao K, et al. Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429‐dependent m6A modification of CCR9. Journal of Medical Virology. 2024. doi:10.1002/jmv.29894

BibTeX
@article{Lv2024,
  author = {Lv, Zhao and Liu, Lijuan and You, Jian and Zhou, Ping and Su, Yaru and Zhao, Kexin and Zhang, Jiahang and Zhu, Fan},
  title = {Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429‐dependent m6A modification of CCR9},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29894}
}
Kostenlos starten →